Correlation between XRCC1 gene Arg194Trp polymorphism and platinum-based chemotherapy in patients with gastric cancer

ZHONG Lan; HUANG Tao; XIE Xianhe; FU Shengmiao; GAO Yunsuo; WU Hua; ZHONG Peijun

doi:10.3969/j.issn.1002-266X.2017.08.002

Abstract：Objective To explore the correlation between X-ray cross complementing repair gene 1 (XRCC1) gene Arg194Trp polymorphism and platinum-based chemotherapy in patients with gastric cancer.Methods Eighty patients with gastric cancer who underwent platinum-based chemotherapy were selected,and the XRCC1 genotypes were detected by multiplex PCR and ligase detection reaction (LDR).All patients were treated with oxaliplatin-based first-line chemotherapy.Accorded to the curative effect standard of gastric cancer treatment,the patients were divided into the platinum sensitive group and platinum resistance group,and the correlation between XRCC1 gene Arg194Trp polymorphism and platinumbased chemotherapy was analyzed.Results There were three kinds of genotypes in XRCC1 gene Arg194Trp:Arg/Arg,Arg/Trp,and Trp/Trp,their distribution frequencies were 42.5％ (34/80),50％ (40/80),and 7.5％ (6/80),respectively.The proportional distribution of the three genotypes met genetic equilibrium law of Hardy-Weiberg,and the experimental subjects were representative.There were no significant differences in sex,age,histological type,TNM stage,chemotherapy regimen in patients with Arg/Arg,Arg/Trp,and Trp/Trp genetypes (all P ＞ 0.05).In 80 patients,platinum drug sensitivity (CR + PR) was found in 39 patients (48.8％),and platinum drug resistance (SD + PD) in 41 patients (51.2％).The sensitivity of platinum drugs in patients with Arg/Trp and Trp/Trp genotypes was significantly higher than that in patients with Arg/Arg genotype (P ＜ 0.05),and there was no significant difference between Arg/Trp and Trp/Trp genotypes in patients (P ＞0.05).Conclusion The XRCC1 gene Arg194Trp is related with the sensitivity of platinum-based drugs in patients with gastric cancer,and the detection of Arg194Trp polymorphism can provide a basis for individual chemotherapy of gastric cancer.